REGN Stock Forecast: Regeneron Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 28 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. hold a median 12-month price target of $1,000 — +8.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 97 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Regeneron Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Accruals (34): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
REGN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on REGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.5% from it.
Of the 20 most recent actions, 19 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | Barclays | Maintains | Overweight | $917 → $1,075 |
| 2 Nov 2026 | B of A Securities | Maintains | Buy | $908 → $1,030 |
| 2 Nov 2026 | Baird | Maintains | Neutral | $761 → $875 |
| 2 Nov 2026 | Bernstein | Maintains | Market Perform | $756 → $812 |
| 2 Nov 2026 | Canaccord Genuity | Maintains | Buy | $922 → $1,175 |
| 2 Nov 2026 | Cantor Fitzgerald | Maintains | Overweight | $795 → $980 |
| 2 Nov 2026 | Evercore ISI Group | Maintains | Outperform | $900 → $1,075 |
| 2 Nov 2026 | Guggenheim | Maintains | Buy | $1,030 → $1,100 |
| 2 Nov 2026 | Leerink Partners | Maintains | Market Perform | $835 → $997 |
| 2 Nov 2026 | Morgan Stanley | Maintains | Equal-Weight | $779 → $855 |
| 2 Nov 2026 | RBC Capital | Maintains | Sector Perform | $810 → $913 |
| 2 Nov 2026 | Truist Securities | Maintains | Buy | $780 → $982 |
| 2 Nov 2026 | Wells Fargo | Maintains | Equal-Weight | $750 → $925 |
| 31 Oct 2026 | JP Morgan | Maintains | Overweight | — |
| 30 Oct 2026 | Citigroup | Maintains | Neutral | $740 → $825 |
| 30 Oct 2026 | JP Morgan | Maintains | Overweight | $950 → $1,050 |
| 28 Oct 2026 | Canaccord Genuity | Maintains | Buy | $875 → $922 |
| 21 Oct 2026 | TD Cowen | Maintains | Buy | $960 → $980 |
| 19 Oct 2026 | Piper Sandler | Maintains | Overweight | $854 → $865 |
| 15 Oct 2026 | UBS | Upgrade | Buy | $660 → $978 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for REGN.
This page is one stock. Monday covers all of them.
REGN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
REGN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Regeneron Pharmaceuticals, Inc. returned +25.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
REGN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 20.4×
- Price / sales
- 5.6×
- Price / book
- 2.8×
- EV / EBITDA
- 15.2×
Cheaper than 44% of US stocks
Cheaper than 19% of US stocks
Cheaper than 33% of US stocks
Cheaper than 33% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 33.5%
- Gross margin
- 86.6%
- Operating margin
- 30.4%
- Net margin
- 28.5%
Higher than 68% of US stocks
Higher than 95% of US stocks
Higher than 88% of US stocks
Higher than 87% of US stocks
- Return on equity
- 14.9%
- Return on assets
- 7.6%
- Dividend yield
- 0.4%
Higher than 74% of US stocks
Higher than 86% of US stocks
Higher than 6% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Regeneron Pharmaceuticals, Inc. has a market value of $95.2B and an enterprise value of $85.8B.
Revenue in the twelve months to 30 June 2026: $15.5B. The latest quarter grew 16.7% year on year.
Net income over the same four quarters: $4.3B, a 27.9% net margin.
Diluted earnings per share, trailing twelve months: $40.46.
Free cash flow in the twelve months to 30 June 2026: $3.6B, after $920.9M of capital spending.
Regeneron Pharmaceuticals, Inc. spent $3.9B on share buybacks and $378.5M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 20.4×; forward P/E: 12.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.41%, paying out 8% of earnings.
Regeneron Pharmaceuticals, Inc. employs 15,410 people — $1.0M of revenue per employee.
Data provided by Twelve Data
REGN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at REGN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Regeneron Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about REGN
What is the REGN stock price forecast for 2026-2027?
The 28 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. have a median 12-month price target of $1,000, with estimates ranging from $812 to $1,175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is REGN stock a buy right now?
Of the 28 analysts covering Regeneron Pharmaceuticals, Inc., 19 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Regeneron Pharmaceuticals, Inc. 97 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank REGN?
As at 21 Nov 2026, Regeneron Pharmaceuticals, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
Will REGN stock go up?
No one can know that. What the data says: the median 12-month target from 28 analysts implies +8.5% from the last close, and Ticker Nerd's factor model ranks Regeneron Pharmaceuticals, Inc. 97 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the REGN stock forecast for 2030?
No analyst covering Regeneron Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $812 to $1,175 over the next 12 months.
How has REGN stock performed over the past year?
Regeneron Pharmaceuticals, Inc. returned +25.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders. The company is known for combining laboratory research, clinical development, and in-house manufacturing to advance biologic therapies and antibody-based medicines. Regeneron also works on product candidates across multiple therapeutic areas, supporting a broad drug pipeline alongside its marketed medicines. Regeneron Pharmaceuticals, Inc. plays an important role in the healthcare market through its focus on specialty therapies designed for complex and often chronic medical conditions.
CEO Dr. Leonard S. Schleifer M.D., Ph.D. · 15,410 employees · United States · https://www.regeneron.com